Convexia GTM brain

category

market profile

• text: Drug asset acquisition requires scientific, commercial and clinical risk evaluation across fragmented data.
• text: Convexia offers component licensing and pilots as it pursues a broader drug development model.

personas

• title: Pharma business development and licensing director
  pains:

  • Promising assets are buried in fragmented sources
  • Manual diligence delays decisions on competitive licensing opportunities
• title: Biotech R&D or translational science lead
  pains:

  • Needs evidence on safety, mechanism and translatability before spending on experiments
  • Must evaluate computational predictions against expert review
• title: Life sciences investment principal
  pains:

  • Must screen many assets with limited scientific diligence capacity
  • Needs a defensible view of market, IP and clinical risk

icp

• text: Pharma and biotech teams seeking in-licensing opportunities or pipeline expansion, especially overlooked preclinical assets.
• text: Life sciences venture and investment groups conducting early asset screening and diligence.

message pillars

• text: Find assets faster across varied sources.
• text: Evaluate candidates using a range of scientific models.
• text: Keep human scientific review in the workflow.
• text: Incorporate operational risk before a trial begins.

objections

• objection: Can model outputs support consequential licensing decisions?
  response: Use predictions as diligence inputs, compare with known assets and have scientific, clinical and regulatory experts independently review the evidence.
• objection: Do we have to buy the whole platform?
  response: The company says individual components can be licensed and offers pilots.
• objection: Does a predicted probability prove a drug will succeed?
  response: No. Treat the estimate as a model output requiring validation against underlying data and real-world outcomes.

competitors

• name: Insilico Medicine
  why: AI-enabled drug discovery and development platform competing for pharma partnerships.
• name: Isomorphic Labs
  why: AI drug discovery partner for pharmaceutical companies.
• name: Formation Bio
  why: Technology-enabled drug development and acquisition of clinical assets.

keywords

• drug asset sourcing software
• AI pharmaceutical due diligence
• biotech asset licensing
• in silico drug evaluation
• AI clinical trial risk
• drug discovery probability of success

voice

• Ambitious and speed-oriented
• Technical with commercial context
• Emphasizes expert review

signals

• text: Pharma company announces a search for external pipeline assets or a licensing mandate.
• text: Biotech fund is building a new investment pipeline or needs faster diligence capacity.

stack

• ESM-3
• RFdiffusion
• Boltz-2
• AlphaFold

pricing

motion

channels

• LinkedIn
• YC launch
• direct sales
• pilots

confidence

Founders

• name: Ayaan Parikh
  title: Founder/CEO
  role: CEO
  bio: Building agents to find and acquire early-stage drug assets. Stanford CS + Bio Built 3 healthtech startups (telemedicine, addiction recovery, hydroponic systems). Published 4 papers on molecular dynamics. Biotech VC and consulting experience.
• name: Rahul Vijayan
  title: Founder/CTO
  role: CTO
  bio: Building agents to find and acquire early-stage drug assets. Stanford CS + Econ Built 3 healthtech startups (telemedicine, gamified recovery, hydroponic systems).